Sekar Kathiresan, Verve CEO

Gene edit­ing for heart dis­ease: Verve kicks off land­mark base edit­ing tri­al

Verve Ther­a­peu­tics has dosed the first pa­tient with its lead car­dio­vas­cu­lar drug, mark­ing a ma­jor mile­stone for the next-gen gene edit­ing tech­nique known as base …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.